International Journal of Pharmacy & Therapeutics

IJPT

ENHANCEMENT OF DISSOLUTION RATE OF CEFIXIME TRIHYDRATE BY USING VARIOUS SOLID DISPERSION TECHNIQUES

Brahmaiah B*, Karlapudi Sreenivasulu, M.Rajwardanreddy, M. Sai sowjanya, Sreekanth Nama, Chandu Baburao

Department of Pharmaceutics, Priyadarshini Institute of Pharmaceutical Education & Research (PIPER), 5th Mile, Pulladigunta, Kornepadu (V), Vatticherukuru (M), Guntur-522017, Andhra Pradesh, India.

ABSTRACT

The aim of this research wok is to formulate and evaluate Cefixime Trihydrate solid dispersions system by using the different techniques. This will increase the solubility of the drug or Cefixime Trihydrate and give the immediate release of the drug from the formulations. The main objective is to formulate a drug product as immediate release oral solid dosage form of Cefixime Trihydrate solid dispersion system which is considered to be stable, robust quality and enhanced dissolution rate. To optimize the method of manufacture by formulate the Cefixime Trihydrate solid dispersion system by various techniques like Physical mixing, Co-grinding, Kneading and solvent evaporation techniques. The disintegrating agent used in the present study is Croscarmellose sodium. To study the dissolution of Cefixime Trihydrate solid dispersion system by using the Physical mixing, Co-grinding, Kneading and solvent evaporation techniques, Optimization of formula. Among the four different techniques used for preparation o solid dispersions solvent evaporation technique has shown the increase in dissolution rate that is the Trail-5 was found to have a faster solubility and dissolution property which was prepared by using Croscarmellose sodium as a disintegrant in the ratio of 1:1.

Key Words:- Solid dispersions, Solubility, Dissolution rate, Cefixime Trihydrate, Croscarmellose sodium.

INTRODUCTION

The poor solubility and low dissolution rate of poorly water soluble drugs in the aqueous gastro-intestinal fluids often cause in sufficient bioavailability rather than the limited permeation through the epithelia and the formulation of poorly soluble drugs for oral delivery now presents one of the major challenges tom formulation scientists in the industries (Choiu WL *et al*., 1971).The term solubility is defined as maximum amount of solute that can be dissolved in a given amount of Solvent

quantitatively it is defined as the concentration of the solute in saturated solution at a certain temperature in qualitative terms, solubility may be defined as spontaneous interaction of two or more substances to form a homogenous molecular dispersion (leuner C *et al*., 2000).

Mechanism of action

Cefixime is a semi-synthetic (partially man-made), (Patil *et al*., 1995) oral antibiotic in the cephalosporin family of antibiotics cefixime stops bacteria from multiplying by preventing bacteria from forming the walls that surround them. The walls are necessary to protect bacteria from their environment and to keep the

---

Corresponding Author

B. Brahmaiah
Email:- brahmaiahmph@gmail.com

141

Brahmaiah B. *et al*. / *International Journal of Pharmacy & Therapeutics*, 4(3), 2013, 140-147.

contents of the bacterial cell together; bacteria cannot survive without a cell wall.

Solid Dispersions

The term solid dispersion refers to a group of solid products (Ford JL *et al*., 1986) consisting of at least two different components, generally a hydrophilic matrix and a hydrophobic drug. The matrix can be either crystalline or amorphous. The drug can be dispersed molecularly, in amorphous particles (clusters) or in crystalline particles (Arora SC *et al*., 2010).Therefore, based on their molecular arrangement, six different types of solid dispersions can be distinguished. They are described in Table 2. Moreover, certain combinations can be encountered, i.e. in the same sample; some molecules are present in clusters while some are molecularly dispersed (Kang BK *et al*., 2010).Moreover, not the preparation method but the molecular arrangement governs the properties of solid dispersions (Broman E *et al*., 2001).

Advantages of solid dispersion

Particles with reduced particle size, Particles with improved wettability, Particles with higher porosity, Drugs in amorphous state.

Preparation Methods of Solid Dispersions

(a) Solid dispersion techniques.
(B) Solvent evaporation method.
(c) Fusion method/melting method.
(d) Hot melt extrusion.
(E) Supercritical fluid technology (SCF).
(F) Dropping method.
(g) Electrostatic Spinning Method. (H) Co-precipitation method.

MATERIALS AND METHODS
Materials Used

Cefixime Trihydrate (Pellets Pharma Ltd), Croscarmellose Sodium (Diocon Pharma Ltd), Distilled Water, Methanol, Di - Chloro methane, Potassium Di-hydrogen Phosphate, Sodium Hydroxide.

Instruments Used

Digital Balance – Semsung AN ISO 9001-2004, Tray Dryer – ELITE scientific, Dissolution apparatus – VEEGO, U-V spectrophotometer – Spectro 2080 plus Analytical technologies limited, Distillation Tank – JSGW double distillation plant.

EXPERIMENTAL METHODS
Estimation of Cefixime Trihydrate

A Simple Sensitive and accurate spectrophotometric method was used for the measurement of Cefixime Trihydrate at a λ max 288nm.The absorbance of standard dilutions were measured at 288nm.

Procedure

The standard solutions of Cefixime Trihydrate were subsequently diluted with pH 7.2 Phosphate buffer to obtain series of dilutions containing 5,10,15,20, and 30 μg of Cefixime Trihydrate solution (suprax *et al.,* 2001). The absorbances of above dilutions were measured in Spectro 2080 plus Analytical technologies limited U-V Spectrophotometer at 288 nm using distilled water as blank. The concentration and the corresponding absorbance values were given in Table 5. The absorbance values were plotted against concentration of Cefixime Trihydrate as shown in Figure -2.

Drug Release Studies

Dissolution studies on each formulation were performed in a calibrated eight station dissolution test apparatus equipped with paddles employing pH 7.2 phosphate buffers as medium. The paddles were operated to rotate at 75 rpm and the temperature was maintained at 37 ± 1^0c throughout the experiment. Samples were withdrawn at regular intervals up to 60 min and replaced with equal volume to maintain the constant volume of dissolution medium throughout the experiment. Drug content of the samples was determined by Spectro 2080 plus Analytical technologies ltd UV Spectrophotometer at 288nm after suitable dilution of samples (Alia *et al.,* 1991). Necessary corrections were made for the loss of drug due to each sampling. The drug dissolved experiments were conducted in triplicate. The dissolution profile were depicted in Table-12 to 13 and shown in Fig-13. The zero order and first order plots and their corresponding release constant were given in Table – 6 to 10 and shown in Figure-3 to 12.

Dissolution Test Acceptance Criteria

Acceptance criteria for dissolution tests are set on the basis of requirements for a percent quantity of drug to be released after a certain period of time in the dissolution apparatus. Since each test is usually conducted using six individual dosage units, acceptance criteria must be established on this basis. The compendia recognize that reasonable tolerances are required to ensure that criteria are not prohibitive, but at the same time, they need to discriminate between acceptable and unsatisfactory batches of products. The approach developed within various compendia is now harmonized for immediate release and extended release—though not for delayed

release—and allows for three levels of staged testing. For immediate release products, acceptance criteria are based on a single time point and a single value, expressed as a Q value (buck tong G *et al.,* 1995). Then, at each of the three stages, the specification requires that mean values not be less than Q, but a set number of individual units are allowed to release a percent quantity of active which may be as low as Q - 25% for one unit at stage three.

For extended release products, specifications are based on three or four time points. For the intermediate time points, the requirements are based on ranges; for the final time point, they are usually based on a single value. Therefore, the acceptance criteria at each stage are expressed in terms of variances around ranges for intermediate time points and minimum acceptable release at the final time point.

Determination of Amount of Drug Content
The amount of drug substance present in the given dissolution samples were determined with the help of UV-Spectrophotometer at a wavelength of 288nm. The obtained absorbance values were substituted in the given equation to get the amount of drug substance at different time intervals of dissolution.

$$Amount= \frac{Test\ o.d}{Standard\ o.d} \times dilution\ factor \times 900/1000$$

Procedure for Assay
The amounts of drug present in the taken oven formulations were determined with the help of UV Spectro photometric method. For each batch 100 mg of sample was taken in to the volumetric flask and add methanol and the mixer was diluted with the pH 7.2 phosphate buffer. The dilutions are made as 5, 10, 15, 20 and 25µg/ml. The absorbance of solution was determined at 288 nm by U-V Spectrophotometer. The resultant drug content and practical yield was shown in the Table 11.

Different Formulation Batches
Formulation 1 - Pure Drug (100mg)

Formulation 2 – Drug: Polymer (1:1) Croscarmelose Sodium
Physical Mixing
Accurately weighed required amount of Cefixime Trihydrate and Croscarmelose Sodium (carrier) in 1:1 drug-to-carrier weight ratio were mixing thoroughly in a mortar until a homogeneous mixture was obtained for 3 min. The product was kept in desiccators at room temperature until for further study or investigation.

Formulation 3 - Drug: Polymer (1:1) Croscarmelose Sodium
Co-grinding Technique
Required quantity of drug was accurately weighed and transferred in to mortar to this adds requires quantity of Croscarmelose sodium in the ration of 1:1 were mixing thoroughly until a homogenous mixer was obtained. Triturating was carried in 10 -15 min to form a homogenous mixer. The product is packed and kept in a dedicator at room temperature until for further study or investigation.

Formulation 4 - drug: Polymer (1:1) Croscarmelose Sodium
Kneading method
Drug and polymer was mixed with the small amount of the solvent i.e. water to form a thick paste by kneading and hence it was dried at 45ºC in a tray dryer. The mass was passed through the sieve no. 30 and stored in the desiccators. The product is packed and kept in a dedicator at room temperature until for further study or investigation.

Formulation 5 – Drug: Polymer (1:1) Croscarmelose Sodium
Solvent evaporation method
Required amount of drug is accurately weighed and transfer in to mortar. The drug and the polymer were dissolved in sufficient volume of dichloromethane with continuous stirring. The solvent was then completely evaporated at room temperature with continuous stirring to obtain dry granules. The resulting solid dispersion was stored in airtight container till further use.

Table 1. Formulation 2 (Physical mixing).

S.No	Ingredients	Quantity
1	Cefixime Trihydrate	100mg
2	Croscarmelose sodium	100mg

Table 2. Formulation 3 (Co-grinding technique)

S.No	Ingredients	Quantity
1	Cefixime Trihydrate	100mg
2	Croscarmelose sodium	100mg

Table 3. Formulation 4 (kneading method)

S.No	Ingredients	Quantity
1	Cefixime Trihydrate	100mg
2	Croscarmelose sodium	100mg
3	Distilled Water	Quantity sufficient

Table 4. Formulation 5 (solvent evaporation method)

S.No	Ingredients	Quantity
1	Cefixime Trihydrate	100mg
2	Croscarmelose sodium	100mg
3	Dichloromethane	Quantity sufficient

Table 5.Calibration Curve for Cefixime Trihydrate in methanol (N=6)

S.No	Concentration (µgm/ml)	Absorbance
1	0	0
2	5	0.106
3	10	0.209
4	15	0.136
5	20	0.415
6	25	0.52

Table 6. Kinetic Profile of Cefixime Trihydate F-1(Pure Drug)

S.No	Time	OD	Amount of drug dissolved	%Drug dissolved	%Drug remained	Log% Drug remained
1	0	0	0	0	100	2
2	5	0.195	83.97	84.78	15.22	1.182
3	10	0.203	81.41	88.25	11.75	1.070
4	15	0.213	91.72	83.34	16.66	1.221
5	20	0.227	97.75	98.69	1.31	0.117

Table 7. Kinetic Profile of Cefixime Trihydate F-2(Physical Mixing) Solid Dispersion

S.No	Time	OD	Amount of drug dissolved	%Drug dissolved	%Drug remained	Log% Drug remained
1	0	0	0	0	100	2
2	5	0.206	88.70	89.17	10.83	1.034
3	10	0.219	94.30	94.80	5.2	0.716
4	15	0.222	100	-	-	-

Table 8. Kinetic Profile of Cefixime Trihydate F-3 (Cogrinding) Solid Dispersion

S.No	Time	OD	Amount of drug dissolved	%Drug dissolved	%Drug remained	Log% Drug remained
1	0	0	0	0	100	2
2	5	0.213	88.70	74.89	25.11	1.4
3	10	0.232	97.38	91.72	8.28	0.918
4	15	0.230	99.04	100	0	-

Table 9. Kinetic Profile of Cefixime Trihydate F-4 (Kneading Method) Solid Dispersion

S.No	Time	OD	Amount of drug dissolved	%Drug dissolved	%Drug remained	Log% Drug remained
1	0	0	0	0	100	2
2	5	0.199	85.69	85.77	14.23	1.153
3	10	0.210	90.43	90.52	9.48	0.976
4	15	0.226	97.32	100	2.59	0.413

144

Brahmaiah B. *et al*. / *International Journal of Pharmacy & Therapeutics*, 4(3), 2013, 140-147.

Table 10. Kinetic Profile of Cefixime Trihydate F-5 (Solvent Evaporation Method) Solid Dispersion

S.No	Time	OD	Amount of drug dissolved	%Drug dissolved	%Drug remained	Log% Drug remained
1	0	0	0	0	100	2
2	5	0.183	78.80	94.24	25.70	1.41
3	10	0.201	96.52	100	5.675	0.754

Table 11. Assay of Cefixime Trihydrate

S.No	Formulation	Drug content	Practical yield
1	F1	94 mg	93
2	F2	89.8 mg	91.6
3	F3	90.72	91.03
4	F4	90.28	91.33
5	F5	93.31	94.18

Table 12. Dissolution parameters

S.No	TRAILS	Zero Order				First Order		
		PD10 (%)	T50 (min)	Regression (R)	Ko (mg/ml)	Slope (b)	R	K1 (min⁻¹)
1	F-1	88.25	4	0.898	1.88	0.0917	0.9942	0.087
2	F-2	94.8	3.3	0.982	4.79	0.128	0.9608	0.022
3	F-3	100	3	0.992	2.73	0.108	0.998	0.077
4	F-4	90.52	3.5	0.899	0.762	0.0987	0.9702	0.126
5	**F-5**	**100**	**3**	**0.991**	**10**	**0.1246**	**0.9995**	**0.55**

Table 13. Dissolution Data

S.No	Time (min)	% Drug Dissolved				
		F1	F2	F3	F4	F5
1	**0**	0	0	0	0	0
2	**5**	83.97	88.70	74.89	85.77	94.24
3	**10**	81.41	94.30	91.72	90.52	100
4	**15**	91.72	100	100	100	-
5	**20**	97.75	-	-	-	-
6	**30**	**100**	-	-	-	-

Figure 1. Dissolution Apparatus

Figure 2. calibration curve for estimation of cefixime trihydrate

calibration curve of cefixime trihydrate

**Figure 3. Zero Order Kinetic Profile of Cefixime Trihydate F-1(Pure Drug)**

**Figure4. Zero order kinetic profile of Cefixime Trihydate f-2(physical mixing) solid dispersion**

**Figure 5. Zero Order Kinetic Profile of Cefixime Trihydate F-3 (Cogrinding) Solid Dispersion**

Figure-6-Zero Order Kinetic Profile of Cefixime Trihydate F-4 (Kneading Method) Solid Dispersion

Figure 7. Zero Order Kinetic Profile of Cefixime Trihydate F-5 (Solvent Evaporation Method) Solid Dispersion

Figure 8. First Order Kinetic Profile of Cefixime Trihydate F-1(Pure Drug)

Figure-9- First Order Kinetic Profile of Cefixime Trihydate F-2(Physical Mixing) Solid Dispersion

146

Brahmaiah B. *et al*. / *International Journal of Pharmacy & Therapeutics*, 4(3), 2013, 140-147.

Figure 10. First Order Kinetic Profile of Cefixime Trihydate F-3 (Cogrinding) Solid Dispersion


Figure 11. First Order Kinetic Profile of Cefixime Trihydate F-4 (Kneading Method) Solid Dispersion


Figure 12- First Order Kinetic Profile of Cefixime Trihydate F-5 (Solvent Evaporation Method) Solid Dispersion


**Figure13. Comparative First Order Dissolution Profile**

Figure 14. Comparative Dissolution Profile

DISCUSSION
Trail-1

This trail was done by using pure drug; it has shown poor dissolution property because of less solubility of drug in the dissolution medium.

Improvisation: As pure drug has shown poor dissolution property, in order to enhance the dissolution rate we used different methods for preparing solid dispersions.

Trail -2

147

Brahmaiah B. *et al*. / *International Journal of Pharmacy & Therapeutics*, 4(3), 2013, 140-147.

In this trail solid dispersion of drug was prepared by using Croscarmelose sodium as a disintegrant in the ratio of 1:1 and by using Physical mixing method. Maximum drug release was observed at time 15 min. **Improvisation**: Further this formula was optimized for enhancing the drug release by using other technique.

Trail-3

In this trail solid dispersion of drug was prepared by using Croscarmellose sodium as a disintegrant in the ratio of 1:1 and by using Co–grinding method. Maximum drug release was observed at time 15 min. **Improvisation**: Further this formula was further optimized for enhancing the drug release by using other technique.

Trail-4

In this trail solid dispersion of drug was prepared by using Croscarmellose sodium as a disintegrant in the ratio of 1:1 and by using kneading method. Maximum drug release was observed at time 20 min. **Improvisation**: Further this formula was further optimized for enhancing the drug release by using other technique.

Trail-5

In this trail solid dispersion of drug was prepared by using Croscarmellose sodium as a disintegrant in the ratio of 1:1 and by using Solvent evaporation method. Maximum drug release was observed at time 10 min. Hence the trial 5 which was prepared by using Croscarmellose sodium and drug by the ratio of 1:1 by using solvent evaporation was found to be optimized formula.

CONCLUSION

This study was undertaken with an aim to formulate an Anti-Biotic drug in the form solid dispersion to overcome the poor solubility drawback of the drug. The selected Antibiotic agent was Cefixime Trihydrate. The drug Cefixime Trihydrate is having poor solubility in the water, under class 2 of BCS of classification of drug its solubility was tried to increase by formulating in the form of solid dispersion with polymer by using various techniques. Solid dispersions were prepared by using the Croscarmelose sodium as a disintegrant in 1:1 ratio of different techniques.

Among the four different techniques used for preparation o solid dispersions solvent evaporation technique has shown the increase in dissolution rate that is the Trail-5 was found to have a faster solubility and dissolution property which was prepared by using Croscarmellose sodium as a disintegrant in the ratio of 1:1. Hence finally it was concluded that Trail-5 as an optimized formula with an increased rate of dissolution rate and solubility. Trail 5 which is prepared by using drug and disintegrant ratio of 1:1 ratio by using solvent evaporation techniques.

REFERENCES

Amidon GL, Lennernas H, Shah VP and Crison JR, Theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *J Pharma Res*, 12(3), 1995, 413-420.

Arora SC. Development, characterization and solubility and solid dispersions of cefixime trihydrate by solvent method. *Int. J of DDR*, 2(1), 2010, 424- 430.

Breitenbach J, Melt extrusion from process to drug delivery system. *J Pharma Res*, 12(5), 2002, 1269-1292.

Broman E, Khoo C, and Taylor LS. A Comparison of alternative polymer excipients and processing methods for making solid dispersion of poorly water soluble drug. *Int. J Pharm*, 221(1), 2001, 139-151.

Buck ton G and Darcy P, The use of gravimetric studies to asserts the degree of crystalanity of predominantly crystalline powder. *Int. J. Pharm,* 123(2), 1995, 265-271.

Chiou WL and Riegelman S. Pharmaceutical applications of solid dispersion systems, *J. Pharm. Sci*, 60(9), 1971, 1281-1302.

Ford JL. The current status of solid dispersions. *Pharm Acta Helva*. 61(1), 1986, 69-88.

Ghaderi R, Artursson P and Carifors J. Preparation of biodegradable micro particles using solution enhanced dispersion by supercritical fluids (SEDS). *J Pharm. Res,* 16(4), 1999, 676-681.

Karavas E, Ktistis G, Xenakis A and Georgarakis E. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. *Eur. J. Pharm. Biopharm*, 63(2), 2006, 103-114.

Leuner C and Dress man J. Improving drug solubility for oral delivery using solid dispersions *Eur. J. Pharm. Biopharm*, 50(4), (2000), 47-60.

Luenberger H. Spray freezed drying the process of choice for low water soluble drugs, *J of nano partical research,* 4(4), 2002, 111-119.

Patil *et al.,* Improvement in dissolution efficiency of poorly soluble naproxen. *The Eastern Pharmacist*, 521, 2001, 107-110.

Sethia S and Squillante E. Physiochemical Characterization of solid dispersion of Carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. *J. Pharm. Sci,* 91(9), 2002, 1948-1957.